Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT04527380 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04527380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04527380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 13, 2021
Completion date
January 31, 2029
Enrollment
101 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

enthesitis related arthritis, juvenile psoriatic arthritis